RESEARCH TRIANGLE PARK, N.C., April 17, 2009 (GLOBE NEWSWIRE) -- Icagen, Inc. (Nasdaq:ICGN) today presented results of the Company’s Phase I program for ICA-105665, the Company’s lead drug candidate for the treatment of epilepsy and neuropathic pain, at the Antiepileptic Drug Trials X Conference in Coral Gables, Florida.
